{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:16:30Z","timestamp":1794604590959,"version":"4.9.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>A 65-year-old man with oligometastatic prostate cancer underwent radical prostatectomy and stereotactic body radiation therapy (SBRT) to a right pubic bone metastasis. Four weeks after SBRT, PSMA PET showed increased extent and intensity of uptake at the treated site, despite a 92% PSA decline (8.5 to 0.7\u00a0ng\/mL) and no new lesions. Later imaging confirmed resolution of uptake, consistent with bone flare, but revealed multiple new osseous metastases and rising PSA (2.8\u00a0ng\/mL), indicating progression. To our knowledge, this is the first reported case of SBRT-induced bone flare, highlighting the need for cautious interpretation of early posttreatment PSMA PET.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006447","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:00:10Z","timestamp":1775671210000},"page":"e793-e794","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic Body Radiation Therapy (SBRT)-Induced 68Ga-PSMA PET Bone Flare"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1693-3854","authenticated-orcid":false,"given":"Valentina","family":"Marulanda-Corzo","sequence":"first","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Sharbatdaran","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology and Oncology, New York-Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Huicochea-Castellanos","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"R1-20260803","first-page":"747","article-title":"Effects of radiation therapy on bone lesions as measured by 47 ca and 85 Sr local kinetics","volume":"13","author":"Greenburg","year":"1972","journal-title":"J Nucl Med"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2214\/ajr.142.4.773","article-title":"The flare phenomenon on radionuclide bone scan in metastatic prostate cancer","volume":"142","author":"Pollen","year":"1984","journal-title":"AJR Am J Roentgenol"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003072-199007000-00006","article-title":"Leuprolide therapy for prostate cancer. An association with scintigraphic \u201cflare\u201d on bone scan","volume":"15","author":"Johns","year":"1990","journal-title":"Clin Nucl Med"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00259-010-1576-0","article-title":"The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer","volume":"38","author":"Cook","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2019.4636","article-title":"Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide: secondary analysis of the PREVAIL and AFFIRM randomized clinical trials","volume":"6","author":"Armstrong","year":"2020","journal-title":"JAMA Oncol"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fmed.2019.00342","article-title":"Feasibility study and preliminary results of prognostic value of bone SPECT-CT quantitative indices for the response assessment of bone metastatic prostate carcinoma to abiraterone","volume":"6","author":"de Laroche","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.18632\/oncotarget.2558","article-title":"Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"5","author":"De Giorgi","year":"2014","journal-title":"Oncotarget"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/RLU.0000000000004107","article-title":"Bone and lymph node flare to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer on 18F-prostate-specific membrane antigen PET\/CT with decreasing prostate-specific antigen of 0.7 ng\/mL","volume":"47","author":"Lu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [(18)F]PSMA-1007 PET\/ CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naive metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/RLU.0000000000002273","article-title":"Bone flare to androgen deprivation therapy in metastatic, hormone-sensitive prostate cancer on 68Ga-prostate-specific membrane antigen PET\/CT","volume":"43","author":"Zacho","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/RLU.0000000000001966","article-title":"Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET\/CT examinations in castration-resistant prostate cancer: first observations","volume":"43","author":"Zukotynski","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/RLU.0000000000005104","article-title":"Pluvicto-induced 18 F-PSMA PET bone flare","volume":"49","author":"Wang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"1758835920987654","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:01:51Z","timestamp":1785787311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006447","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"2025-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}